These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18180847)

  • 21. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intensive insulin therapy].
    Landgraf R; Huber RM; Bachmann A; Lohr R
    Dtsch Med Wochenschr; 2008 Apr; 133(17):901-12. PubMed ID: 18415916
    [No Abstract]   [Full Text] [Related]  

  • 23. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y; Guo XH; Vaz JA;
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy to prevent type 1 diabetes mellitus.
    Rodriguez-Villar C; Casamitjana R; Conget I
    N Engl J Med; 2002 Oct; 347(14):1115-6. PubMed ID: 12362943
    [No Abstract]   [Full Text] [Related]  

  • 25. Oral hypoglycaemic agents in the treatment of immunogenic insulin resistance in NIDDM.
    Ramachandran A; Snehalatha C; Mohan V; Rao CA; Viswanathan M
    Diabete Metab; 1987 Apr; 13(2):140-1. PubMed ID: 3595969
    [No Abstract]   [Full Text] [Related]  

  • 26. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C; Gilbride CJ
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
    Goldberg RB; Fonseca VA; Truitt KE; Jones MR
    Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
    Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
    Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Blood pressure and type 2 diabetes mellitus: impact of the insulin therapy].
    Dakhli S; Lamine S; Lamine F; Trabelsi N; Aouididi F; Zouaoui C; Mami FB; Achour A
    Tunis Med; 2007 Nov; 85(11):945-50. PubMed ID: 19166146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.
    Yang WY; Ji QH; Zhu DL; Yang JK; Chen LL; Liu ZM; Yu DM; Yan L
    Chin Med J (Engl); 2009 Jul; 122(14):1704-8. PubMed ID: 19719975
    [No Abstract]   [Full Text] [Related]  

  • 39. 2008 resource guide. Insulin. Along with human insulin analogs, recombinant DNA human insulins are the most widely used insulins in this country. Through genetic engineering, bacteria or yeast are transformed into little "factories" that produce synthetic human insulin.
    Diabetes Forecast; 2008 Jan; 61(1):RG11-4. PubMed ID: 18290288
    [No Abstract]   [Full Text] [Related]  

  • 40. [Acquired insensitivity to treatment with oral hypoglycemica in type 2 diabetes. Etiopathogenetic aspects].
    Motta L; Lombardo A; Trischitta V; Scavino S; Oliva G; Scornavacca G
    Minerva Endocrinol; 1984; 9(2):205-12. PubMed ID: 6503907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.